Introduction
Most qualitative research exploring narratives of HIV treatment experience has centred on settings in which HIV treatment access is relatively secure (Davies, 1997; Ezzy, 2000) . Such research has focused primarily on the renegotiation of personal and health identities in light of treatment potential and success (Brashers et al., 1999; Carricaburu & Pierret, 1995; Selwyn & Arnold, 1998; Siegal & Lekas, 2002) . More recently, qualitative research has explored the influence of ''treatment optimism'' on risk behaviour, (Elford, Bolding, & Sherr, 2002) and how HIVpositive individuals engage with medical knowledge relating to their HIV treatment (Brashers et al., 2003; Davis, 2007; Davis, Frankis, & Flowers, 2006; Kielmann et al., 2005; Rosengarten, Miris, Flowers, Davis, & Hart, 2004; Tiamson, 2002) .
Clinical uncertainty has been a dominant feature of the HIV treatment experience (Brashers et al., 2003; Chidwick & Borrill, 1996; Crossley, 1998; Davis et al., 2006; Kielmann et al., 2005; Weitz, 1989) . In resourcerich settings, this uncertainty has been prescribed by technological advances in treatment and underpinned by individual adaptation to medical innovation (Davis et al., 2006) . However, the experience of HIV treatment in secure delivery settings is unlikely to be directly translatable to settings in which consistent access to treatment, due to social and economic constraints, is itself uncertain.
The unprecedented challenge of scaling-up HIV treatment in resource-constrained settings has meant that research has predominately focused on demonstrating the viability of HIV treatment in such settings (Curran et al., 2005; Thimothy, Kumar, & Irudaya Rajan, 2006) , monitoring treatment delivery and targets, and supporting individuals' treatment adherence (Chesney, 2003) . However, given the lifelong nature of HIV treatment once initiated, research is needed to understand how HIV treatment decisions are managed in the context of competing constrained resources. Qualitative evidence emerging from South Africa demonstrates that HIV treatment is ''juggled'' alongside other competing needs, with individuals strategically rationing treatment to maintain financial survival, sometimes by staying ''ill enough'' to retain a disability grant (Leclerc-Madlala, 2006) .
Despite intensive efforts to strengthen treatment delivery infrastructures, the fragility of some health systems have been exposed by the staggering scale of HIV treatment scale-up. This has been compounded by donor dependency and substantial logistical obstacles. Treatment security is an ongoing concern in many regions. In Uganda, experience of shortages in state funded HIV treatment have led senior national highly active anti-retroviral treatment (HAART) procurement managers to call for individuals to save money to cover their own purchases of rationed drug supplies (Kasanga & Bainemigisha, 2006) . There are frequent reports in resource-constrained settings of treatment shortfalls resulting from delivery blockages, financial problems and human error (IRIN, 2006a (IRIN, , 2006b (IRIN, , 2007 Kyokuhaire, 2006) .
There is scant research that focuses on the social impact of fragile treatment delivery and a need for a social science of scale up. The aim of this qualitative study was to explore what impact fragile delivery of HIV treatment has upon the experience of living with HIV in Serbia and Montenegro.
Methods
Between October 2005 and November 2006, we undertook a qualitative study among 41 people living with HIV (PLHIV) and 18 HIV treatment providers in Serbia and Montenegro. The study comprised indepth qualitative interviews among a purposively selected sub-sample of participants.
Setting
South Eastern Europe, including Serbia and Montenegro, has recently experienced large-scale social and economic disruption, including political transitions contextualised by conflict and uncertainty, resulting in population displacement and increased health vulnerability. The HIV epidemic in South Eastern Europe is small in comparison to Eastern Europe but there are parallels in the risk environment (Rhodes & Simic, 2005) . In 2006, there were 1250 PLHIV registered in Serbia and Montenegro. Six hundred patients received care at the one HIV clinic in the country, 520 of whom received HAART (Simic, 2006) . Treatment has been state funded since 2002. HAART was prescribed one month at a time from this clinic and administered by the National Central Pharmacy. Monitoring tests for CD4 and PCR were intermittently available. The frequency of testing varied amongst patients between three times/ year to not at all. We describe constraints relating to the treatment system elsewhere (Bernays, Rhodes, & Prodanovic, 2007) .
Sampling and recruitment
Recruitment was via contacts with local NGOs (21) and snowballing within PLHIV networks (14). Through these avenues 40 PLHIV were approached, with five refusing to participate. In order to reach those outside of these networks we also advertised for participants at the national HIV clinic (6). Recruitment and data collection were undertaken in three waves to enable provisional coding to inform the focus of ongoing recruitment and data collection.
Over half of the HIV-positive participants were living in Belgrade at the time of the study, where approximately 70% of the HIV population of Serbia and Montenegro reside (Simic, 2006) . Participants from outside Belgrade were recruited from areas in north and southern Serbia (Vojvodina, n 08; Nis, n04), and from Montenegro (n 05). The age of participants ranged from 22 to 78 years, with the median age being 35 years old.
We also recruited 18 HIV treatment service providers (SPs). These comprised key national representatives of the treatment supply chain, as well as specialist HIV medical staff and NGO personnel.
Data collection
Data collection was via in-depth interviews, most of which (30/41) took place in participants' homes. Interviews were facilitated by a topic guide, and designed to explore participants' narratives. Key areas of discussion included: HIV diagnosis; treatment history; experience of HIV treatment and health care; attitudes towards and experience of disclosing status; and HIV community activity. Interviews were tape-recorded and undertaken in Serbian (15), via translation (21) and in English when requested by the participant (5). Additional core structured questions were asked in relation to sample characteristics. All participants were reimbursed 7 Euros for their participation.
Analysis
All interviews were transcribed verbatim and translated for coding and analysis. We assessed the quality of translation by transcribing and translating both the participants' and translators' responses in the first 10 interviews conducted via simultaneous translation, and very little divergence in the articulation of responses was found.
The analysis of data was thematically driven. Key emerging themes included; uncertainty, diminished trust, rationing and individualisation. Initial first level coding was undertaken by the authors and second level coding largely sought to break down first level coding into smaller units. Analytical bias was addressed through the transparent organisation and categorisation of data using word processing software and justifying themes with reference to negative cases (Silverman, 2000) . In order to protect participants' anonymity, interviewees are identified by a number and whether they are HIV positive (PLHIV) or a SP.
Ethics
The study had ethical approval from the Charing Cross Hospital Ethics Committee and in the absence of an ethics committee approval was given by the Ministries of Health, and Republican AIDS Commissions, of Serbia and Montenegro. All interviews were conducted with informed consent.
Results

Fragile access to continuous HIV treatment
There was a consensus in participant accounts that HIV treatment medications and monitoring tests were not continuously available, and that this was a consequence of supply shortages. HIV treatment providers employed two strategies to manage treatment shortages. One was to stop treatment until the appropriate medication became available again. The alternative strategy was to change the regimen of treatment. The sporadic availability of monitoring tests made these decisions even more precarious:
''The treatments are just each month what they have in the pharmacy . . . without any medical check you know, without any check of blood or some support so that you can see those tests say, 'OK you can take that'. It is a very big problem. Now my treatment is available at the pharmacy but I don't know for how long''. (PLHIV 33) The unpredictability of supplies made planning patients' treatment very difficult: ''We can't have any plan, because we don't know when supplies will fail'' (SP 9). In this environment of fluctuating supplies, the distribution of treatment was uneven: ''Some people can get medicines and some can't'' (PLHIV 33). Treatment was therefore experienced by PLHIV as individualising and intensely uncertain: ''It is like waiting in a line and you really don't know if your turn is going to come'' (PLHIV 28). This anxiety was felt amongst all participants and there was no gender-specific variation.
In response to this, PLHIV also themselves engaged in a rationing process. Whilst in some cases such constrained resources were a cause of ''tension between people'', in other cases it facilitated informal friendship networks as people exchanged treatment amongst themselves.
HIV treatment uncertainty
The perceived fragility of the HIV treatment system caused almost unanimous concern amongst PLHIV. Participants' accounts emphasised the perennial ''fear'' and ''uncertainty'' that they experienced in relation to the continuity and sustainability of supplies: Despite the theme of anxiety linked to HIV treatment uncertainty being unanimous across the accounts of PLHIV, there was disagreement in the accounts of SPs as to the gravity of the treatment situation. Some SPs felt that the fragile treatment situation seriously undermined the quality of life and the capacity PLHIV had to manage HIV as a manageable chronic illness: ''I think it has terrible impact. They were afraid all the time. Some of them are in a really bad condition'' (SP 3). Crucially this was said to have negative influence on participants' trust in the effectiveness of HAART: ''They don't believe in this therapy here after that [treatment shortages]'' (SP 4).
Others, generally those working within or representing the treatment system, acknowledged the problem but contextualised it alongside a spectrum of problems facing resource-stretched Serbia and Montenegro. These latter accounts emphasised that treatment expectations should be adjusted from an international ideal to a locally realistic level:
''It's not the correct way but . . . we can not live like in France, and we must deal with it, doctors also must deal with it . . . The patients are happy to have treatment, any treatment''. (SP 2)
Rationing treatment information
We found that the uncertainty recounted by participants was exacerbated by a perceived lack of authority and trust in relation to the information available about HIV treatment. Participants described available information as being ''unreliable'' or ''based on gossip'':
''The talk with people and in the media is always these terrifying headlines like: There won't be any medicines; or There won't be enough money for HIV treatment. I feel this influences the psychological state of people, they fall into depression. They feel they have no future''. (PLHIV 34) In a context of frequent and alarmist rumours concerning HIV treatment shortages and low treatment literacy, a lack of faith in the authority of information available fostered an atmosphere of confusion and fear for many PLHIV about how best to manage HIV treatment opportunities and the consequences of interrupted drug courses. In the absence of reliable information sources and with reportedly low use of the Internet, most relied upon the national HIV clinic. Yet due to the high workload of the three HIV specialists, opportunities to discuss treatment or supplies with patients were rare. Additionally, information about the consequences of treatment interruption and unmonitored switching was deliberately rationed by SPs in order to mediate anxiety:
''Of course it's not good, we know that, but it's not necessary to . . . make them fear''. (SP 2) Access to information about HIV treatment availability appeared unevenly distributed among participants. Information relating to treatment availability is rationed not only by the system, but also between patients, with information about treatment frequently traded like a currency:
''If you are lucky someone remembers to call you and tell you [monitoring tests are available] and then you have to run, run to the clinic! . . . .It is hard when someone is in a better position just because that person has information and so that person can access some service ''. (PLHIV 33) Disengagement from the system Accessing treatment was perceived as the individuals' responsibility. Participants described a lack of accountability amongst senior level SPs to manage treatment supply shortages. We found that this undermined participants' trust in the system and its ability to prevent or react to further shortages. Many interpreted this silence to reflect and further reinforce stigma associated with HIV:
''You don't know who's responsible and then you don't know who to complain to when there aren't any medicines . . . I think that the whole thing is connected with stigma. It's like keep quiet: you've got whatever you get''. (PLHIV 28) The level of distrust in the sustainable provision of supplies meant that even during extended periods of stability the majority of PLHIV continued to perceive treatment access to be insecure and remained anxious about the sustainability of supplies. Subject to the state's perceived inability to provide them with appropriate treatment without interruption, many characterised their situations as being liminal, fluctuating between a manageable chronic illness and a terminal illness.
''Many of my friends were also on a treatment interruption because we did not have medicines. We started to be desperate at that time because somebody who has been on treatment for a few years, suddenly they found hope again and when you don't have treatment everything is lost''. (PLHIV 1)
The individualisation of treatment
We identified three principal strategies employed by participants to manage their HIV treatment uncertainty. The first strategy was to invest significant time and energy fostering networks and resources, such as spending a great deal of time at the HIV clinic, to ensure optimum access to information and treatment. This acted as a form of social capital to generate security: ''It depends how much someone is pushing. There are the patients who have tests regularly'' (PLHIV 34). The second was to continue with treatment but ration contact with other PLHIV and HIV related service provision in order to mediate the risk of anxiety by ''avoiding other PLHIV'' and alarming rumours: ''Other than what I hear from the doctors I won't allow anything else [information] to come near me'' (PLHIV 27). The third strategy adopted by a few participants was to stop taking treatment or choose not to start because they saw the situation as too precarious and ''more risk than things to gain'' (SP 3).
The individualisation of treatment and its uncertainties interplays with weak social and community support for PLHIV. The involvement of PLHIV in NGOs, self-support groups and HIV community action is relatively weak in Serbia and Montenegro (Bernays et al., 2007) . SP accounts attributed this to PLHIV's concerns around the disclosure risks of being involved. Whilst this was a factor, PLHIV themselves placed far greater emphasis on needing to prioritise their time and energy for ''chasing treatment''. As one person active in community action explained:
''People won't come! And now I know why: it's not just the thing if someone will see them or not, if they will give their name, but the thing is that they can hardly survive, have the therapy each month! If we had it for six months, and took it monthly, if I could go each month and say: 'Hello, I'm here to get my medicines'. . . . but like this when you're thinking every month about it, you can hardly think of self-318 S. Bernays and T. Rhodes help groups, some volunteer work, and paid work ''. (PLHIV 40) Community support organisations were generally perceived to have a low life expectancy: ''Just like the medicines they are a blink of hope'' (PLHIV 1). The lack of trust in their longevity further undermined participants' motivation to risk disclosure by participating in community action.
Discussion
The individuation of treatment
We found that uncertain or inconsistent treatment access contributed to patient anxiety, which in an absence of reliable information about treatment or trust in the treatment system, fostered the ''individualisation'' of treatment. Individuals absorbed the anxieties resulting from system weaknesses. The unsystematic distribution of treatment resources meant that access, to a certain extent, depended on individuals' efforts to foster relations with medical staff and their peer networks.
Various forms of ''rationing'' emerged as a strategy to manage treatment uncertainty as well as access to treatment. We identified three forms of rationing: information; expectation; time/energy. Information about treatment was rationed by SPs to PLHIV, and among PLHIV, where information about treatment was traded like a currency. Expectations, as well as hope, were rationed on the basis of the experience of treatment uncertainty and system failure becoming habituated in a setting of transition and resource constraint. The time and energy of PLHIV was largely absorbed by managing HIV treatment access and uncertainty, and was thus rationed elsewhere, including in relation to HIV community participation.
The implications of inconsistent treatment
Current evidence, underpinned by findings which prompted the premature cessation of the SMART study (Crabb, 2006) , suggests a need for continuous adherence to HIV treatment to minimise treatment failure and maintain long-term health (Pai, Lawrence, Reingold, & Tulsky, 2006) . Strategies of unmonitored stopping and treatment switching in order to temporarily respond to supply gaps therefore raise serious concerns (Martin & Sim, 2005) .
In addition, this study emphasises the social impact of inconsistent treatment. We found that the perceived failure of the treatment system to deliver can foster a relinquishing of trust in treatment expertise, which in turn may limit expectation and discourage motivation and adherence. Treatment needs to be perceived as effective and sustainable if it is to contribute to tackling stigma . For example, improved access to treatment in resource-constrained settings has helped encourage HIV community participation (Lange, Perriens, Kuritzkes, & Zewdie, 2004) and HIV testing (WHO, 2003) . Our study suggests that the motivation PLHIV have to challenge stigma through open disclosure and community action is weakened because they are consumed with the physical and psychological effort of surviving the liminal state of fragile treatment opportunity.
In order to better capture the fluidity of the treatment situation we are conducting a follow-up study with multiple interviews to capture the impact over time. Data from a follow-up study indicate that the situation is improving, due to the implementation of longer-term procurement and financing plans, but availability issues still recur and anxieties persist.
Conclusion
HIV treatment scale up creates a heavy burden on relatively weak health care infrastructures (Kim & Farmer, 2006; Knapp, 2004) . This qualitative study is one of few (Bayer & Oppenheimer, 2007) to explore the lived experience of uncertain HIV treatment in a context of resource constraint. It shows that fragile access to HIV treatment, and the resulting uneven nature of the treatment experience, can have significant influence on participants' perceptions of their health and quality of life.
The generalisability of our findings is grounded in the specific sample and setting of our study. However, they may have relevance to other settings in which HIV treatment access or delivery is inconsistent and where patient or provider rationing in relation to treatment occurs. Our findings show that insecure treatment delivery can individualise the struggle of PLHIV and undermine community participation efforts to advocate for improved treatment and tackle stigma. This is likely to have an impact on HIV prevention efforts as well as the lives of PLHIV.
